Royalty Pharma (RPRX) reported Q3 net income Wednesday of $544 million, up from $72 million a year earlier.
Comparable analysts' estimates were not available.
Total income and other revenue for the quarter ended Sept. 30 was $565 million, up from $536 million a year earlier.
Three analysts polled by Capital IQ expected $731.8 million.
As of Sept. 30, the company said it had $950 million in cash and cash equivalents.
Royalty Pharma shares were up 3.1% in recent Wednesday premarket activity.
Price: 27.94, Change: +0.84, Percent Change: +3.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。